Epix contrast agent re-named AngioMark

Article

Epix Medical of Cambridge, MA, and Mallinckrodt of St. Louis announced last month that MS-325, an MRI contrast agent under development at Epix, will be sold in the U.S. and Europe by Mallinckrodt under the trade name AngioMark. The drug is currently in

Epix Medical of Cambridge, MA, and Mallinckrodt of St. Louis announced last month that MS-325, an MRI contrast agent under development at Epix, will be sold in the U.S. and Europe by Mallinckrodt under the trade name AngioMark. The drug is currently in clinical trials, and trademark applications are pending. AngioMark will be used with MR angiography for visualization of arteries and veins. Mallinckrodt and Epix hope the agent will improve the diagnosis of atherosclerotic occlusive disease.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.